 |
PDBsum entry 4ybk
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
|
|
Title
|
|
Conformation-Selective analogues of dasatinib reveal insight into kinase inhibitor binding and selectivity.
|
|
|
Authors
|
|
F.E.Kwarcinski,
K.R.Brandvold,
S.Phadke,
O.M.Beleh,
T.K.Johnson,
J.L.Meagher,
M.A.Seeliger,
J.A.Stuckey,
M.B.Soellner.
|
|
|
Ref.
|
|
Acs Chem Biol, 2016,
11,
1296-1304.
[DOI no: ]
|
|
|
PubMed id
|
|
|
|
|
|
Abstract
|
|
|
In the kinase field, there are many widely held tenets about
conformation-selective inhibitors that have yet to be validated using controlled
experiments. We have designed, synthesized, and characterized a series of kinase
inhibitor analogues of dasatinib, an FDA-approved kinase inhibitor that binds
the active conformation. This inhibitor series includes two Type II inhibitors
that bind the DFG-out inactive conformation and two inhibitors that bind the
αC-helix-out inactive conformation. Using this series of compounds, we analyze
the impact that conformation-selective inhibitors have on target binding and
kinome-wide selectivity.
|
|
|
|
|
|
|
